DAY 1
Wednesday, June 25th 2025
8h00
Registration and welcome coffee
8h40
Welcome Address
- Descartes Auditorium
8h50
OPENING KEYNOTE LECTURES
- Descartes Auditorium
To Be Announced
Elsa Kress
Head of Business Development
MabDesign, France
Antibodies to Watch in 2025: Mid-year update with a focus on ADCs and Unconventional ADCs
Silvia Crescioli
Business Intelligence Creator
The Antibody Society, USA
Biomarkers of response and resistance to ADCs across solid tumors
Barbara Pistilli
MD, Chair of the Breast Cancer Unit
Gustave Roussy , France
10h00
Coffee Break at Exhibition Hall
10h30
Discovery and optimization of Ms/Bs Abs, ADCs, Immunocytokines, and Next-Gen anti-PD-1
- Descartes Auditorium
Session I
Bispecific antibodies engaging the adaptive and innate immune systems via CD28 and CD47 targeting
Nicolas Fischer
CEO
Light Chain Bioscience, Switzerland
Cis-Demasking Cytokine Technology for Targeted Delivery with nextGen anti-PD1
Silvia Comis
Head of Clinical Development and Regulatory Affairs
OSE Immunotherapeutics, France
Boosting CD3-Targeting Bispecific Antibodies: Exploring Synergistic Combination Partners
Abdullah Elsayed
Group Leader
Philochem AG, Switzerland/ Italy
Leveraging cutting-edge DNA technologies to build precision libraries for antibody engineering
Radha Parmar
Science & Technology Consultant, Biologics - EMA
Twist Bioscience, USA
Antibody development against challenging targets such as GPCR, channels, etc
- Pasteur Room
Targeting gonadotropin receptors with single domain antibodies to control reproduction and treat associated dysfunctions
Eric Reiter
DR1, PhD, Deputy director of UMR PRC, BIOS team
MUSCA team (INRIA/INRAE/CNRS), INRAE Centre Val de Loire, Nouzilly, France
A first in class anti-Follicle Stimulating Hormone potentiating therapeutic antibody as a breakthrough treatment for fertility
Elodie Kara
R&D Project Manager
IGYXOS, France
Tiny but Mighty ! Single domain antibodies for cancer imaging and immunotherapies
Patrick Chames
Team Leader Antibody Therapeutics and Immunotargeting
Marseille Cancer Research Center, France
Comprehensive and Reliable Characterization of Antibody Therapeutics thanks to Kimialys's innovative SPR biochips
Claude Nogues
CSO & Co-founder
Kimialys, France
12h10
Lunch at Exhibition Hall
13h00
Workshop :Bridging Innovation to the Clinic: Smart First-in-Human Dose Selection for Novel Targeted Therapeutics
- PASTEUR ROOM
Lionel Renaud
PK/PD and Systems Pharmacology Modeler
LYO-X, Switzerland
Saeed Masroor
Scientist in Quantitative Systems Pharmacology
LYO-X, Switzerland
14h00
Discovery and optimization of Ms/Bs Abs, ADCs, Immunocytokines, and Next-Gen anti-PD-1
- Descartes Auditorium
Session II
Novel best in class therapeutic antibodies targeting novel antigens by their Primary B-Cell Screening Platform
Michael Koslowski
CEO
Kling Biotherapeutics, The Netherlands
TUB-040, a Napi2b-targeting ADC currently tested in clinical trials, shows long-lasting anti-tumor efficacy via Topoisomerase-I inhibition and excellent tolerability
Björn Hock
Chief Development Officer
Tubulis, Germany
INA03: A potent transferrin-competitive ADC against CD71 for safer Acute Leukemia treatment. How to transform a undruggable to a druggable target
Pierre Launay
CSO
Inatherys, France
Challenges and opportunities in alternative delivery approaches
- Pasteur Room
A multidisciplinary perspective on subcutaneous biologics delivery
Sylvain Huille
BioPharmaceutics Development France
SANOFI, France
Topical Application of Nebulized Polyclonal IgG: from Proof of Concept into Clinical Development
Anna Schnell
Senior Scientist
CSL Behring, Switzerland
VHH to treat brain disorders and how they can go through the BBB
Philippe Rondard
Team Leader, Neuroreceptors: Dynamics and Functions
Institut de Génomique Fonctionnelle, France
15h40
Coffee Break at Exhibition Hall
16h00
Pitch Session : Innovative Approaches and New trend Technologies
- Descartes Auditorium
Call for Abstracts - Deadline April 4th 2025 !
Assessing the immunomodulatory effects of Immune Checkpoint Antibodies using 3D cell co-culture models
Marcin Krzykawski
CEO
Real Research, Poland
Generation of nano-antibodies using extracellular vesicles for diagnostic purposes
Clara Bouyx
Post-Doc CNRS (Operations manager of the LabCom NVDIAG)
Laboratoire d'Ingénierie des Systèmes Macromoléculaires (LISM), France
APL-1030, a Novel High-Affinity Nanofitin Inhibitor of C3-Mediated Complement Activation
Mathieu Cinier
CSO
Affilogic, France
Effector cell redirection (heme/solid)
- Pasteur Room
Update on NKp46 engager
Laurent Gauthier
Senior Director, Research and Development
Innate Pharma, France
Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity
Cyrille Dreyfus
Associate Director
Ichnos Glenmark Innovation, Switzerland
MAIT T-cell engagers: Providing an effective therapeutic window to treat solid tumors
Simon Plyte
Chief Scientific Officer
Biomunex Pharmaceuticals, France
17h30
Round table - Enhancing Investment Understanding
- Descartes Auditorium
Maxence de Vienne
Partner
Elyan
18h20
Investor's Pitch - Private session
- Pasteur Room
19h00
Poster Presentation - Dinner Cocktail Reception at Exhibition Hall
20h30
Announcement of « BEST POSTER »
21h00
End of DAY 1
DAY 2
Thursday, June 26th 2025
8h00
Welcome coffee
8h30
Fc domains of mAbs, ADCs, and BsAbs : Potency, Safety, Regulatory & IP
- Descartes Auditorium
Fc-mediated functions modulation of mAbs, ADCs, BsAbs and Fc-fusion proteins
Alain Beck
Senior Director, Biologics CMC & developability
Pierre Fabre , France
Still living in LALA land? Are there better ways to eliminate unwanted Fc effector functions?
Geoff Hale
CEO
mAbsolve, UK
Studying structure/function relation of therapeutic antibodies using LC and MS
Koen Sandra
CEO
RIC Group, Belgium
The confusing patent landscape regarding Fc domain domain engineering: ADCC, serum half life and more
Ulrich Storz
Senior Partner - Patent Attorney
Michalski Huettermann, Germany
Biomarkers development for next-generation Antibodies treatments
- Pasteur Room
Clinical and molecular biomarkers for optimization cohorts in early-phase oncology trials
Elisa Fontana
MD, PhD, Hospital Medical Director
Sarah Cannon Research Institute in London, UK
Molecular imaging to get insight into (modified) antibody behavior in patients
Derk Jan de Groot
MD, PhD, Medical Oncologist
UMCG Universitair Medisch Centrum Groningen, The Netherlands
Navigating In-vitro Diagnostics Regulation (IVDR) frameworks in early drug development
Rafael Grochot
MD, MSc, Medical Oncologist
Sarah Cannon Research Institute in London, UK
10h00
Coffee Break at Exhibition Hall
10h30
Non-conventional ADCs
- Descartes Auditorium
Enhancing therapeutic index of antibody-drug conjugates through site-specific DAR1 conjugation
Sergii Kolodych
Chief Scientific Officer
Syndivia, France
Antibody-Vincristine Conjugates as Potent Anticancer Therapeutic Agents
Alain Wagner
Research Director
BioFunctional Chemistry Team, University of Strasbourg, France
Antibody Fragment Drug Conjugates: Next-Generation ADCs Tailored for Solid Tumours
Mahendra Deonarain
CEO
Antikor Biopharma Ltd, UK
Mechanisms of resistance to ADCs, ADA, and biomarker-driven versus payload resistance
- Pasteur Room
Novel Multi-Payload ADCs Assembled in One Step from Native Antibodies that Show Excellent Biophysical Properties and High Efficacy in vivo
Philipp Spycher
Founder and CSO
Araris Biotech AG, Switzerland
Antibody Conjugates in Oncology and Beyond
Christian Kunz
Vice President Biologics Discovery
Ridgeline Discovery, Switzerland
Unlocking the potential of artificial intelligence in antibody discovery
Thomas Bourquard
CSO and co-founder
MabSilico, France
12h00
Lunch at Exhibition Hall
13h00
Round Table "Nourrir l'innovation : Attirer et recruter les meilleurs talents dans l'industrie du Biomédicament"
- Barthez Auditorium
14h00
AI-based computational approaches to Antibody Discovery & Optimization and accelerating Clinical Trials
- Descartes Auditorium
To Be Announced
Astrid Musnier
Co-founder & Head of Biology
MAbSilico, France
To Be Announced
Zoya Alteber
Director Research and drug Discovery
Compugen Ltd, Israel
Powering explainable AI to optimize biological prescriptions and drug development in IBD using real-world data
Fréderic Parmentier
VP of Data Science
Ariana Pharma, France
Emerging 3D preclinical models
- Pasteur Room
Patient-Derived tumour Explants as a preclinical model system for predicting patient responses to advanced therapies
Catrin Pritchard
Professor of Cancer Biochemistry
Leicester Cancer Research Centre, University of Leicester, UK
Hydrogel droplet microfluidic approach for high-throughput drug screening in spheroids
Guillaume Mottet
Senior Director of Biologics Discovery
Microfluidics Team, SANOFI, France
In Vivo New Alternative Methods (NAMs) for Drug Evaluation: From Cancer Cell Line 3D Models to Patient Tumor Avatars
Jean Viallet
CEO
INOVOTION, France
15h40
Closing Keynote
- Descartes Auditorium
Bispecific Antibodies against infectious diseases
Luca Varani
Structural Biology Group Leader
Institute for Research in Biomedicine, Switzerland
16h10
Announcement of AIS2026
16h30
